Omalizumab and cancer risk: Current evidence in allergic asthma, chronic urticaria, and chronic rhinosinusitis with nasal polyps

Diego Bagnasco, MD, PhD; Rikki Frank Canevari, MD; Stefano Del Giacco, MD; Silvia Ferrucci, MD; Paolo Pigatto, MD; Paolo Castelnuovo, MD; Gian Luigi Marseglia, MD; Arzu Didem Yalcin, MD; Girolamo Pelaia, MD; Giorgio Walter Canonica, MD

World Allergy Organization Journal (Dec 2022)

Omalizumab and cancer risk: Current evidence in allergic asthma, chronic urticaria, and chronic rhinosinusitis with nasal polyps

Diego Bagnasco, MD, PhD,
Rikki Frank Canevari, MD,
Stefano Del Giacco, MD,
Silvia Ferrucci, MD,
Paolo Pigatto, MD,
Paolo Castelnuovo, MD,
Gian Luigi Marseglia, MD,
Arzu Didem Yalcin, MD,
Girolamo Pelaia, MD,
Giorgio Walter Canonica, MD

Affiliations

Diego Bagnasco, MD, PhD: Allergy and Respiratory Diseases, Department of Internal Medicine (DIMI), University of Genoa, Italy; IRCCS Policlinico San Martino, Genoa, Italy; Corresponding author. Allergy and Respiratory Diseases, IRCCS San Martino, University of Genoa, Genoa, Italy
Rikki Frank Canevari, MD: IRCCS Policlinico San Martino, Genoa, Italy; Unit of Otorhinolaryngology-Head and Neck Surgery, University of Genoa, Genoa, Italy
Stefano Del Giacco, MD: Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy
Silvia Ferrucci, MD: Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy
Paolo Pigatto, MD: Clinical Dermatology, IRCCS Istituto Ortopedico Galeazzi, Milan, Italy
Paolo Castelnuovo, MD: Division of Otorhinolaryngology, Department of Biotechnology and Life Sciences, University of Insubria, Ospedale di Circolo e Fondazione Macchi, Varese, Italy
Gian Luigi Marseglia, MD: Pediatric Clinic, Fondazione IRCCS Policlinico “S. Matteo,” University of Pavia, Pavia, Italy
Arzu Didem Yalcin, MD: Division of Allergy and Immunology, Department of Internal Medicine, Antalya Education and Research Hospital, University of Health Sciences, Antalya, Turkey
Girolamo Pelaia, MD: Department of Health Sciences, Magna Graecia University, Catanzaro, Italy
Giorgio Walter Canonica, MD: Personalized Medicine Center, Asthma and Allergy, Humanitas Clinical and Research Center, IRCCS, Rozzano, Milan, Italy

Journal volume & issue: Vol. 15, no. 12
p. 100721

Abstract

Read online

Omalizumab is a biological drug targeting circulating IgE, approved for use in allergic asthma, chronic spontaneous urticaria, and recently for chronic rhinosinusitis with nasal polyps, with good efficacy in all these settings. Some concerns about omalizumab safety have been raised as its use has been recently linked to potential increased cancer risk. Nevertheless, literature evidence does not support this statement, and clinical studies and evidence from real-world registries and surveillance analysis have consistently reported drug safety.

Published in World Allergy Organization Journal

ISSN: 1939-4551 (Online)
Publisher: Elsevier
Country of publisher: Netherlands
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Immunologic diseases. Allergy
Website: https://www.sciencedirect.com/journal/world-allergy-organization-journal

About the journal

Abstract

Keywords